Gold Intraday: Up Trend Threatened by Vaccine Progress

On Wednesday, spot gold dropped as much as $30 from the day-high after Pfizer's vaccine results announcement and ended down 0.6% on day.

Trader 1

On Wednesday, U.S. pharmaceutical giant Pfizer and German biotech company BioNTech announced early positive data of its Covid-19 vaccine. Spot gold dropped as much as $30 from the day-high after the announcement and ended down 0.6%.

Pfizer said if the ongoing studies are successful and the vaccine receives regulatory approval, they "expect to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021".

Unlike the previous vaccine study results released by Moderna in May, scientists praised Pfizer for publishing the data and said the results support progressing to a larger clinical trial.

From an intraday technical point of view, spot gold risks breaking below a longer-term rising trend line as shown on the 1-hour chart. Another RSI bearish divergence is spotted when it marked a new high near $1,789. Unless the nearest resistance at $1,778 is surpassed, which is the 61.8% Fibonacci retracement resistance level of yesterday's decline, spot gold is likely to challenge the 1st and 2nd support at $1,759 and $1,747 respectively. Alternatively, a break above $1,778 might suggest that the next resistance at $1,789 would be tested again.

Source: TradingView, Gain Capital

More from Gold


This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.

GAIN Capital Singapore Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the GAIN Capital group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), GAIN Capital Singapore Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact GAIN Capital Singapore Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.

In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither GAIN Capital Singapore Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.

GAIN Capital Singapore Pte. Ltd. is not under any obligation to update this report.

Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit for the complete Risk Disclosure Statement.

Important Notice:

Cryptocurrencies are not legal tender currency and trading of derivatives on Cryptocurrencies are currently not covered under any regulatory regime in Singapore. Consequently, investors should be aware they do not have protection under the Securities and Futures Act (Cap. 289). Please ensure that you are fully aware of the risks.